If you are managing type 2 diabetes or obesity alongside a cancer diagnosis, you are probably very familiar with GLP-1 receptor agonists. These popular medications—including Ozempic, Wegovy, Mounjaro, Zepbound, and Trulicity—have completely changed how we manage blood sugar and weight.
Now, groundbreaking data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting suggest these drugs might do something entirely unexpected: help prevent early-stage cancers from spreading.
Here is what this study found, what it means for your health, and what to discuss with your doctor.
Nearly one in five people with cancer also has diabetes, according to the Centers for Disease Control and Prevention. Diabetes and obesity cause metabolic dysfunction, including elevated blood sugar, elevated insulin levels, and chronic, low-grade systemic inflammation. Unfortunately, this creates an ideal environment for cancer cells to grow and spread.
While GLP-1 drugs are well known for controlling blood sugar and reducing appetite, they also have powerful anti-inflammatory effects. Researchers wanted to see if these properties could actively protect patients who already have an early-stage cancer diagnosis.
“GLP-1 receptor agonists have never been just glucose-lowering drugs. Their anti-inflammatory and immune-modulatory properties have long suggested broader effects. What’s new here is the consistency across tumor types, and data this large and this consistent warrant a prospective randomized trial,” said Marcin Chwistek, MD, FAAHPM, Chief of Supportive Oncology and Palliative Care Program at Fox Chase Cancer Center and an ASCO Expert in supportive care.
The study tracked patients who initiated one of the following GLP-1 receptor agonists (or the amylin analog pramlintide, which was grouped in the exposure arm) after their cancer diagnosis:
Note: These patients were compared 1:1 against a highly similar control group taking DPP-4 inhibitors (gliptins), such as sitagliptin (Januvia) or linagliptin (Tradjenta).
Researchers looked at the global health records of more than 12,000 people diagnosed with Stage I, II, or III cancers, a cohort that included 20 to 25 percent were Black or African American. Half of these patients started a GLP-1 drug after their cancer diagnosis, while the other half took an older class of diabetes medication called a DPP-4 inhibitor (gliptin).
The goal was to see which group was less likely to progress to Stage IV (metastatic) cancer, which means the cancer has spread to other parts of the body.
For four major types of cancer, patients taking GLP-1 drugs saw a massive drop in the risk of their cancer spreading:
The study also looked at prostate, pancreatic, and kidney cancers. While fewer patients on GLP-1s saw their cancer spread in these groups too, the numbers weren’t large enough for scientists to be absolutely certain the drug was the cause.
Yes, according to this data. A common concern with GLP-1 drugs is stomach or pancreatic inflammation (pancreatitis). However, this study found that patients taking GLP-1s did not experience any higher rates of these side effects than patients taking other diabetes medications, even while undergoing cancer treatment.
1. This is a massive clue, not a cure.
This was an “observational study,” meaning researchers examined existing health records. Because it wasn’t a controlled clinical trial in which patients were randomly assigned to a drug, it cannot definitively prove that GLP-1s caused the slowdown in cancer. More rigorous clinical trials are currently being planned to confirm these results.
2. Do not stop or start a medication without your oncology team.
If you are currently taking a GLP-1 drug for diabetes or weight loss, this study is incredibly reassuring, suggesting that your medication may be providing an extra layer of protection. If you have been considering starting one, this data provides an excellent talking point for your next appointment.
If you want to bring this up at your next visit, here are a few simple questions to kickstart the conversation:
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
